

Balaxi Pharmaceuticals Limited

October 01, 2023

To,
Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

NSE Symbol: BALAXI

Dear Sir/Madam,

Subject: Update on acquisition of Balaxi Healthcare Ecuador S.A.S.

This is in reference to our letter dated August 03, 2023, regarding acquisition of Balaxi Healthcare Ecuador S.A.S. and pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In this connection, we hereby inform you that the Company has successfully completed the acquisition of 100% shareholding in Balaxi Healthcare Ecuador S.A.S., an Ecuadorian Company. After completion of the acquisition, Balaxi Healthcare Ecuador S.A.S. has become a Wholly Owned Subsidiary of the Company.

The details required to be furnished under SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, were already intimated vide our letter dated August 03, 2023.

The aforesaid information is also being hosted on the Company's website at www.balaxipharma.in.

This is for your information and records.

Yours Faithfully,

For **Balaxi Pharmaceuticals Limited**

Udayan Shukla
(Company Secretary and Compliance Officer)
Membership No.: F11744

Registered Office:

Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase III, Road No. 81, Jubilee Hills, Hyderabad (T.G.) - 500 096

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in